2021-09-14

Breaking the new record of product development speed of emerging technologies, Triastek’s third in-house developed drug T21 submitted the PIND meeting request to the FDA

2021-07-14

Triastek Closes US$ 50 Million Series B Financing, Co-led by Matrix Partners China and CPE

2021-02-09

MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA

2020-12-15

TRIASTEK RAISES $15M TO ACCELERATE DEVELOPMENT OF 3D PRINTED DRUGS